Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study

Abstract

Background:

Despite the complexity of psoriasis treatment using biologic therapy, there does not exist a standardized synoptic reporting form for the initiation of this population. The purpose of this study was to use a modified Delphi approach to develop a standard checklist for the standardized documentation of patients receiving systemic biologic therapy for psoriasis.

Methods:

A modified Delphi survey was conducted over 3 rounds (February 2017 through January 2018). An expert panel generated a 51-item checklist that was proposed to participants. Items were rated on an anchored 1-7 Likert scale. Consensus was defined apriori as ≥ 70% agreement by respondents.

Results:

A total of 58, 17, and 18 dermatologists participated in 3 consecutive Delphi rounds, respectively. Only half of the dermatologists surveyed reported using a checklist for the management of psoriasis. The final checklist comprised 19, 5, 6, and 9 items pertaining to patient history; physical exam and history of systemic therapy; vaccinations; and lab investigations and bloodwork, respectively.

Conclusions:

Given the increasing availability and complexity of biologic agents for psoriasis treatment, there is a need to promote standardized documentation for this population. The Checklist for the Systemic Treatment of Psoriasis presents 38 items that should be considered when initiating patients with psoriasis on biologic therapy.

Keywords

checklist Delphi plaque psoriasis psoriasis

Get full access to this article

View all access options for this article.

References

Parisi

Symmons

Griffiths

Ashcroft

DM.

Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385. doi:10.1038/jid.2012.339

Kirkham

Furst

Romain

Tumor necrosis factor-alpha inhibitors: An overview of adverse effects. UpToDate. 2019. https://www.uptodate.com/contents/tumor-necrosis-factor-alpha-inhibitors-an-overview-of-adverse-effects. Accessed July 2, 2017.

Gardam

Keystone

Menzies

et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3(3):148-155. doi:10.1016/S1473-3099(03)00545-0

Dreyer

Magyari

Laursen

Cordtz

Sellebjerg

Locht

Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry. Ann Rheum Dis. 2016;75(4):785-786. doi:10.1136/annrheumdis-2015-208490

Kwon

Coté

Cuffe

Kramer

Braun

MM.

Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003;138(10):807-811. doi:10.7326/0003-4819-138-10-200305200-00008

Sârbu

Tampa

Mitran

Limbău

Georgescu

SR.

Adverse reactions of biological therapies in patients with psoriasis. J Mind Med Sci. 2017;4(1):4-12. doi:10.22543/7674.41.P0412

Hohenberger

Cardwell

Oussedik

Feldman

SR.

Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat. 2018;29(1):13-18. doi:10.1080/09546634.2017.1329511

Menter

Gottlieb

Feldman

et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850. doi:10.1016/j.jaad.2008.02.039

American Academy of Dermatology Work Group, Menter

Korman

et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137-174. doi:10.1016/j.jaad.2010.11.055

10.

Papp

Gulliver

Lynde

Poulin

Ashkenas

; Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg. 2011;15(4):210-219. doi:10.2310/7750.2011.10066

11.

Canadian Psoriasis Guidelines Addendum Committee. 2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009. J Cutan Med Surg. 2016;20(5):375-431. doi:10.1177/1203475416655705

12.

Smith

Anstey

Barker

et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161(5):987-1019. doi:10.1111/j.1365-2133.2009.09505.x

13.

Smith

Jabbar-Lopez

Yiu

et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177(3):628-636. doi:10.1111/bjd.15665

14.

Schenkel

Ellis

Arbor

Carter

Pariser

The psoriasis patient narrative study: an update on an ongoing patient-centered outcomes research study exploring the experience of living with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2013;68(4 suppl 1):AB215. doi:10.1016/j.jaad.2012.12.886

15.

Hsu

Sandford

BA.

The Delphi technique: making sense of consensus. Pract Assess Res Eval. 2007; 12(10):1-8.

16.

IBM Corp. Released 2015. IBM SPSS Statistics for Windows, version 23.0. Armonk, NY: IBM Corp.

17.

Rahier

Moutschen

Van Gompel

et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford). 2010;49(10):1815-1827. doi:10.1093/rheumatology/keq183

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.13 MB

0.00 MB